In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Science

Africa’s Geographer Of Genes

Nigerian start-up 54gene seeks to be the first private sector enterprise bent on applying Africa’s rich genetic heritage to solve the world’s most intractable diseases – ethically, without boundaries, for all.

Middle East and Africa Nigeria

Novel Biopharma: What Lies Ahead?

Advanced Therapies have come a long way over the past decade. Some cell and gene therapies have already been approved and others have now entered the later stages of development and this is reflected in a shift towards later clinical trials. In consequence, manufacturing process consistency, GMP standards, etc., must now meet more formal requirements. This brings some challenges because the products, and their development and manufacturing processes, differ from traditional models.

Business Strategies Manufacturing

Building Targeted Chemotherapies: ADCs, ProTides And ‘Click Chemistry’

If targeted therapies for cancer represent a more precise, laser-like attack on solid tumors and blood cancers, cytotoxic chemotherapies are more like a ham-fisted boxer punching every cell in sight. New methods for delivering chemotherapy directly into cancer cells may help to improve efficacy and reduce – or eliminate – damaging and sometimes deadly side effects.    

Innovation Cancer

Future Of Surgery: Virtual Reality, Robotics And Collaboration

Immersive technologies are becoming a reality in the OR. In Vivo explores the future of surgery, profiling innovators of augmented reality technologies and exploring the promise and challenges surrounding robotic surgery as companies try to take technologies to the next level. 

Robotics New Science

Growth Anticipated For RNA Therapies In New Indications

The approval of several novel RNA therapeutics in the last five years and the success of the COVID-19 mRNA vaccines has revived interest in the potential of RNA-based therapies. DTx Pharma hopes to use fatty acid conjugation to improve the delivery and duration of small interfering RNA therapeutics for rare diseases.

Innovation Companies

New Science: Faster Development And Tech Convergence

Stuart Henderson, senior managing director and client lead for Accenture’s global life sciences practice, speaks to In Vivo about the emerging components of a winning biopharma development and portfolio strategy. CEOs are asking: “How do we change the cost of innovation?” says Henderson.

Innovation Digital Health

Medtech’s Place In Health Care R&I Boosted Under Horizon Europe

Cross-industry collaboration is the new focus of EU health care technology research funding activity. Under Horizon Europe, the Innovative Health Initiative will encourage convergence in health technology, and prioritize digital technologies and data analytics. No longer can EU-funded projects be pharma-only or medtech-only, said MedTech Europe’s Patrick Boisseau.

EU Medical Device

Immunomodulating Heat-Killed Bacteria Could Become Staple Of Oncology Treatment

UK-based Immodulon Therapeutics is developing novel immunomodulators in the form of heat-killed bacteria, being trialed in combination with other cancer treatments such as checkpoint inhibitors. The biotech is initially looking at underserved areas, including pancreatic cancer.

C-Suite Speaks ImmunoOncology
UsernamePublicRestriction

Register